This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Genetic markers of statin-induced myopathy	<p>Genetic studies identified SNPs that could help stratify patients based on their risk for statin-induced myopathy. Use of statin drugs such as simvastatin is associated with a small increase in risk of myopathy. In an analysis of gene expression in lymphoblastoid cell lines derived from 480 subjects in a clinical trial of simvastatin, six SNPs at the <i>glycine amidinotransferase</i> (<i>GATM</i>; <i>AGAT</i>) gene locus were associated with decreased risk of statin-induced myopathy. Next steps include assessing the role of <i>GATM</i> in statin-mediated changes to cholesterol metabolism and muscle health.</p> <p>SciBX 6(37); doi:10.1038/scibx.2013.1046 Published online Sept. 26, 2013</p>	Unpatented; licensing status unavailable	<p>Mangravite, L.M. <i>et al. Nature</i>; published online Aug. 28, 2013; doi:10.1038/nature12508 Contact: Lara M. Mangravite, Sage Bionetworks, Seattle, Wash. e-mail: lara.mangravite@sagebase.org</p>